The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
• Subtype M2 AML requires further understanding of its genetic landscape for improved prognostication.
• Identifying tumor-specific mutations is crucial for targeted therapies.

Purpose of the Study:

• To explore tumor-specific mutated genes in acute myeloid leukemia subtype M2 using transcriptome sequencing.
• To investigate the correlation between the AML1-ETO fusion gene and prognosis in AML-M2 patients.
• To analyze recurrent gene mutations and their expression differences before and after treatment.

Main Methods:

• Transcriptome sequencing of bone marrow and peripheral blood samples from 96 AML-M2 patients.
• Real-time fluorescent quantitative RT-PCR to detect the AML1/ETO fusion gene.
• Comparative analysis of gene expression profiles before treatment and after complete remission (CR).

Main Results:

• The AML1-ETO fusion gene was detected in 54.17% of patients.
• Patients with the AML1-ETO fusion gene showed a higher complete remission rate (84.62%) compared to negative patients (77.27%), though not statistically significant.
• Significant differences in gene expression were observed for IDHI, JAK3, ABL1, and BCR genes before and after CR.

Conclusions:

• High-throughput sequencing effectively identifies gene expression differences in AML-M2 patients.
• The AML1-ETO fusion gene expression appears to influence patient prognosis in AML-M2.
• Further research is warranted to elucidate the role of specific gene mutations in AML-M2 pathogenesis and treatment response.